divalproex

Generic: DIVALPROEX SODIUM·Brand: DEPAKOTE, DEPAKOTE CP, DEPAKOTE ER, DIVALPROEX SODIUM

divalproex: sourced relationships with 2 companies · 1 clinical trial tracked · 4 FDA decisions.

What we can confirm

4 FDA records · 1 tracked trial

Choose a linked company to investigate (optional)BioSniper will not guess a linked company.

What it means

More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch active trials and any change in FDA or trial status.

BioSniper AIPage evidence connected

Prepared research question

What is verified about divalproex, and what remains unknown?

Traceable citations · Unknowns marked

Dated Pipeline Records (2)

Company	Dated record stage	Indication
DR REDDYS LABORATORIES LTD (RDY) Reported 2008-07-29 · Current development: unknownSource	Approved	—
Teva Pharmaceutical Industries Limited (TEVA) Reported 2008-07-29 · Current development: unknownSource	Approved	—

Clinical Trial Registry Records (1)

Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

NCT03919292Registry updated 2026-06-29·Phase 1/Phase 2

Suspended

Primary endpoint: Determination of Recommended Phase 2 Dose (RP2D)

Interventionalopen83 targetStarted 2019-05Completion 2031-011 site · United StatesVirginia Commonwealth University

FDA Decisions4 records

Mar 15, 2012

ANDA090161OralTablet, Extended Release

Jan 23, 2009

ANDA078979OralCapsule, Delayed Rel Pellets

Jul 29, 2008

ANDA078755OralTablet, Delayed Release

Jul 29, 2008

ANDA076941OralTablet, Delayed Release

Frequently asked questions

divalproex has dated SEC/FDA relationship records for DR REDDYS LABORATORIES LTD, Teva Pharmaceutical Industries Limited.

BioSniper tracks 1 clinical trial involving divalproex.

The most recent tracked FDA decision for divalproex is Approval, dated March 15, 2012.